GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Arterienrekonstruktion  (1)
  • Cardiovascular Pharmacology, Clinical Studies  (1)
  • 1
    Electronic Resource
    Electronic Resource
    196. Behandlung begleitender Gefäßverletzungen bei Unfallen (1974)
    Springer
    Langenbeck's archives of surgery 337 (1974), S. 849-849 
    Details
    ISSN: 1435-2451
    Keywords: Vascular Injury ; Arterial Reconstruction ; Traumatic Ischemia ; Gefäßverletzung ; Arterienrekonstruktion ; Traumatisch bedingteIschämie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bericht über 314 Eingriffe am Arteriensystem nach Unfällen, davon 35 Aortenverletzungen. Unfallursachen: penetrierende, iatrogene, stumpfe Verletzungen, Verkehrsunfälle. Therapie: primär 40 Ligaturen, 9 Amputationen, 19 mal konservative Behandlung. 246 Arterien warden rekonstruiert. Ergebnis: 183 Rekonstruktionen zeigen gute, 18 eingeschränkte Funktion, 24 Patienten warden amputiert, 31 starben. — 28 Ligaturen zeigen gute Funktion, 5 schlechte Funktion, 6 Patienten warden amputiert, 1 starb. — Die konservativ Behandelten zeigen 9 mal gute, 5 mal eingeschränkte Funktion, 1 Amputation und 3 mal letalen Ausgang.
    Notes: Summary The report deals with 314 vascular operations after accidents, 35 of which involved aortic injury. Etiology: penetrating, iatrogennc, traumatic, following traffic accidents. Treatment: primary ligations in 40, amputation in 9, conservative treatment in 19 patients. Arterial reconstruction was performed in 246 cases. Results: 183 reconstructions resulted in good, 18 in limited function, 24 patients needed amputation, and 31 died. Twenty-eight ligations left good and 5 bad function, 6 patients needed amputation, and 1 died. Of the conservatively treated patients, 9 had good, and 5 had limited function, 1 required amputation, and 3 died.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01278828
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    facet.materialart.
    Unknown
    Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa [Clinical Trials] (2014)
    American Heart Association (AHA)
    Details
    Publication Date: 2014-12-11
    Description: — We evaluated whether droxidopa, a prodrug converted to norepinephrine, is beneficial in the treatment of symptomatic neurogenic orthostatic hypotension, which results from failure to generate an appropriate norepinephrine response to postural challenge. Patients with symptomatic neurogenic orthostatic hypotension and Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa titration (100–600 mg, 3 x daily). Responders then received an additional 7-day open-label treatment at their individualized dose. Patients were subsequently randomized to continue with droxidopa or withdraw to placebo for 14 days. We then assessed patient-reported scores on the Orthostatic Hypotension Questionnaire and blood pressure measurements. Mean worsening of Orthostatic Hypotension Questionnaire dizziness/lightheadedness score from randomization to end of study (the primary outcome; N=101) was 1.9±3.2 with placebo and 1.3±2.8 units with droxidopa ( P =0.509). Four of the other 5 Orthostatic Hypotension Questionnaire symptom scores and all 4 symptom-impact scores favored droxidopa, with statistical significance for the patient’s self-reported ability to perform activities requiring standing a short time ( P =0.033) and standing a long time ( P =0.028). Furthermore, a post hoc analysis of a predefined composite score of all symptoms (Orthostatic Hypotension Questionnaire composite) demonstrated a significant benefit for droxidopa ( P =0.013). There was no significant difference between groups for standing systolic blood pressure ( P =0.680). Droxidopa was well tolerated. In summary, this randomized withdrawal droxidopa study failed to meet its primary efficacy end point. Additional clinical trials are needed to confirm that droxidopa is beneficial in symptomatic neurogenic orthostatic hypotension, as suggested by the positive secondary outcomes of this trial. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00633880.
    Keywords: Cardiovascular Pharmacology, Clinical Studies
    Print ISSN: 0194-911X
    Topics: Medicine
    Published by American Heart Association (AHA)
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...